(Q36573878)

15 August 2017

1 reference

title

Lipid-lowering effects of statins: a comparative review (English)

1 reference

15 August 2017

Michael H Davidson

1

1 reference

15 August 2017

Jennifer G Robinson

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

13

1 reference

15 August 2017

page(s)

1701-1714

1 reference

Statin inhibition of HMG-CoA reductase: a 3-dimensional view

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Comparison of statins in hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Statin safety: an overview and assessment of the data--2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Safety of statins: focus on clinical pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Statin safety and drug interactions: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Azithromycin and terfenadine: lack of drug interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Clinical pharmacokinetics of fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

The effect of erythromycin on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Rhabdomyolysis with concurrent atorvastatin and diltiazem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Interaction between grapefruit juice and midazolam in humans*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

The fate of naringin in humans: A key to grapefruit juice-drug interactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Effects of fibrates on metabolism of statins in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Statin safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Striated muscle safety of ezetimibe/simvastatin (Vytorin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Introduction: rosuvastatin--an efficacy assessment based on pooled trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1701

10.1517/14656566.7.13.1701

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference